Associated Papers
Mapping VEXAS-associated and rare UBA1 variants in the United Kingdom: Insights from patient cohorts and the general population.
Martinez Rodriguez A et al.
British Journal of Haematology, 2026
Clinical Manifestations of VEXAS Syndrome Across a Broad Spectrum of UBA1 Mutation Burden.
Anderson M et al.
Arthritis & Rheumatology (hoboken, N.j.), 2026
Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.
Sakuma M et al.
Leukemia, 2025
Coexistence of VEXAS Syndrome and Chronic Hepatitis B Virus Infection: a Case Report and Literature Review.
Lin K et al.
Clinical Reviews in Allergy & Immunology, 2025
Rapid clinical deployment of UBA1 testing in patients with VEXAS syndrome.
Wadsworth PA et al.
American Journal of Clinical Pathology, 2025
Clonal hematopoiesis meets an autoinflammatory disease: the new paradigm of VEXAS syndrome.
Fiumara M et al.
Expert Review of Hematology, 2025
VEXAS syndrome: A newly identified X-Linked hematoinflammatory disorder - A comprehensive overview of its genetic, molecular, inflammatory, and clinical landscape.
Singh A et al.
Journal of Autoimmunity, 2025
VEXAS: A review of current understandings and emerging treatment strategies.
Holden R et al.
Frontiers in Immunology, 2025
Role of allogeneic hematopoietic cell transplantation in VEXAS syndrome.
Dias AL et al.
Annals of Hematology, 2024
VEXAS without vacuoles: Linking genotype to phenotype.
Zhukovsky S et al.
Ejhaem, 2024
Navigating therapeutic challenges in VEXAS syndrome: exploring IL-6 and JAK inhibitors at the forefront.
Li XX et al.
Molecular Medicine (cambridge, Mass.), 2024
How I diagnose and manage VEXAS syndrome.
Hagiya A et al.
American Journal of Clinical Pathology, 2024
VEXAS-Defining UBA1 Somatic Variants in 245,368 Diverse Individuals in the NIH All Of Us Cohort.
Corty RW et al.
Arthritis & Rheumatology (hoboken, N.j.), 2024
Shared and distinct mechanisms of UBA1 inactivation across different diseases.
Collins JC et al.
The Embo Journal, 2024
VEXAS syndrome: A review of cutaneous findings and treatments in an emerging autoinflammatory disease.
Saad AJ et al.
Experimental Dermatology, 2024
A novel XNA-based Luminex assay to detect UBA1 somatic mutations associated with VEXAS syndrome.
Ma Y et al.
Practical Laboratory Medicine, 2024
VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management.
Koster MJ et al.
American Journal of Hematology, 2024
Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond.
Lacombe V et al.
The Lancet. Haematology, 2024
VEXAS syndrome: Clinical manifestations, diagnosis, and treatment.
Loeza-Uribe MP et al.
Reumatologia Clinica, 2024
Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome.
Chiaramida A et al.
Blood Advances, 2023
VEXAS-Syndrome, a newly described autoinflammatory systemic disease with dermatologic manifestations.
Baur V et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : Jddg, 2023
Shared and Distinct Mechanisms of UBA1 Inactivation Across Different Diseases.
Collins JC et al.
Biorxiv : the Preprint Server for Biology, 2023
Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies.
Sakuma M et al.
Leukemia, 2023
Recurrent Mutations of the Active Adenylation Domain of UBA1 in Atypical Form of VEXAS Syndrome.
Faurel A et al.
Hemasphere, 2023
An update on VEXAS syndrome.
Al-Hakim A et al.
Expert Review of Clinical Immunology, 2023
Estimated Prevalence and Clinical Manifestations of UBA1 Variants Associated With VEXAS Syndrome in a Clinical Population.
Beck DB et al.
Jama, 2023
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.
Papaemmanuil E et al.
The New England Journal of Medicine, 2011